載入中
AMEXHealthcareBiotechnology
最新資料
US$0.994
−US$0.036 · -3.50%
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
前收盤價
US$0.994
−US$0.036 · -3.50%
盤中時間採用ET。市場資料可能有所延遲。
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
日內區間
目前US$0.994
52週區間
目前US$0.994
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
持有
估值
60
合理估值
情緒
53
多空交錯
風險
61
高風險
動能
28
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
日內區間
目前US$0.994
52週區間
目前US$0.994
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1455.6萬 USD | 949.9萬 USD | 894.5萬 USD | 1470.3萬 USD | 389.6萬 USD |
| 銷貨成本 | 84.5萬 USD | 33.4萬 USD | 67.1萬 USD | 72.8萬 USD | 142.6萬 USD |
| 毛利 | 1371.1萬 USD | 916.5萬 USD | 827.4萬 USD | 1397.5萬 USD | 247萬 USD |
| 研究與開發 | 1772.9萬 USD | 1247.2萬 USD | 1570.5萬 USD | 1398.7萬 USD | 3391.4萬 USD |
| 銷售、一般及管理費用 | 1846萬 USD | 1817.1萬 USD | 1730.2萬 USD | 2250.8萬 USD | 1821.2萬 USD |
| 營業費用 | 3549萬 USD | 3064.3萬 USD | 3300.7萬 USD | 3649.5萬 USD | 5168.1萬 USD |
| 利息收入 | 169.1萬 USD | 171.5萬 USD | 162.9萬 USD | 82.9萬 USD | 2000 USD |
| 折舊和攤銷 | 69.9萬 USD | 60.9萬 USD | 69.2萬 USD | 72.7萬 USD | 87.3萬 USD |
| 營業利益 | −2177.9萬 USD | −2147.8萬 USD | −2473.3萬 USD | −2252萬 USD | −4921.1萬 USD |
| 淨利 | −6353.3萬 USD | −1860.9萬 USD | −2148.6萬 USD | −2627.3萬 USD | −4301.9萬 USD |
公司資料更新於 2026年10月11日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI649.81萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM472.23萬0.01%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF322.93萬0.00%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO177.57萬0.01%139.17億 USD0.24%US$356.78+0.94%
iShares Biotechnology ETFIBB149.42萬0.01%108.2億 USD0.44%US$206.49+3.00%
Vanguard Russell 2000 ETFVTWO116.32萬0.01%180億 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC59.46萬0.05%13.17億 USD0.60%US$183+0.11%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC25.06萬0.02%10.45億 USD0.20%US$86.29+0.43%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
